Outset Medical is a leading medtech innovator delivering first-of-its-kind technology into the growing global dialysis market.
Outset Medical is a pioneering medical technology company reimagining dialysis for patients and providers.
Outset Medical was founded in 2010 and is headquartered in San Jose, California.
Outset Medical is dedicated to technology-driven service model innovation aimed at reducing cost and transforming the patient care experience.
Outset’s Tablo System is FDA-cleared for use in acute and chronic care settings. In addition to its acute and chronic care commercial expansion, the company has concluded a clinical trial to expand Tablo’s labeled indication to include home use.
Outset Medical's human-centered model is designed to dramatically improve not only the care experience – for patients, families, providers and physicians alike – but also cost-efficiencies for providers.
Outset Medical is backed by D1 Capital Partners, T. Rowe Price Associates, Fidelity Management and Research Company, Partner Fund Management, Perceptive Advisors and others. Outset Medical went public on Sep 15, 2020, it raised $241.7M at a reported IPO valuation of $2.5B. This follows a $125M Series E financing on Feb 04, 2020, brining Outset's total funding to $447.3M to date.